Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
It is very uncertain whether antibody (T cell) changes treatment adverse events: fever, chill, or malaise after drug… compared with steroid (stratified by antibody type) (very low certainty).
1 finding from 1 review
All‐cause mortality · lung transplant recipients
Polyclonal T‐cell antibody induction showed no clear difference in mortality compared with interleukin‐2 receptor antagonist induction (moderate certainty).
1 finding from 1 review
Acute rejection · lung transplant recipients
Polyclonal T‐cell antibody induction showed no clear difference in acute rejection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
1 finding from 1 review
Infection · lung transplant recipients
Polyclonal T‐cell antibody induction showed no clear difference in infection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
1 finding from 1 review
Bronchiolitis obliterans syndrome · lung transplant recipients
Polyclonal T‐cell antibody induction showed no clear difference in bronchiolitis obliterans syndrome compared with interleukin‐2 receptor antagonist induction (moderate certainty).
1 finding from 1 review
Graft loss censored for death · kidney transplant recipients: first rejection episode
It is very uncertain whether antibody (T cell) + steroid changes graft loss censored for death compared with steroid alone (very low certainty).
1 finding from 1 review
Death · kidney transplant recipients: first rejection episode
Antibody (T cell) + steroid showed no clear difference in death compared with steroid alone (low certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Antibody (T cell) + steroid showed no clear difference in failure of reversal of acute rejection episode compared with steroid alone (low certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: first rejection episode
Antibody (T cell) + steroid showed no clear difference in recurrent rejection compared with steroid alone (low certainty).
1 finding from 1 review
Graft loss or death with a functioning graft · kidney transplant recipients: first rejection episode
It is very uncertain whether antibody (T cell) + steroid changes graft loss or death with a functioning graft compared with steroid alone (very low certainty).
1 finding from 1 review
Acute rejection, steroid resistant/antibody treated As reported in the articles · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower acute rejection, steroid resistant/antibody treated As reported in… compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Acute rejection · lung transplant recipients
IL‐2 receptor antagonist induction showed no clear difference in acute rejection compared with no antibody induction (moderate certainty).
1 finding from 1 review
Bronchiolitis obliterans syndrome · lung transplant recipients
IL‐2 receptor antagonist induction showed no clear difference in bronchiolitis obliterans syndrome compared with no antibody induction (moderate certainty).
1 finding from 1 review
All‐cause mortality · lung transplant recipients
IL‐2 receptor antagonist induction showed no clear difference in mortality compared with no antibody induction (moderate certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Neurological adverse effects · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review